Cutaneous Lymphoma. Curtis T. Thompson, MD 6/9/2010

Similar documents
Non-Hodgkin s Lymphoma

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

Oncology Best Practice Documentation

Malignant Lymphomas and Plasma Cell Myeloma

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

Resident Short Reviews. Subcutaneous Panniculitis-like T-Cell Lymphoma

Immunohistochemical classification of malignant lymphomas

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

Cutaneous Lymphoma FAST FACTS

Lymphoma Diagnosis and Classification


B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

Subclassifying DLBCL. Diffuse Large B-Cell Lymphoma: Variants & Subtypes. Subclassifying DLBCL

Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms

Leukemias and Lymphomas: A primer

Cutaneous B-cell lymphoma: classification, prognostic factors and management recommendations. Nancy J. Senff

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Non Hodgkin Lymphoma:

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition

Immunodiagnostyka w rozrostach układu krwiotwórczego - rola cytometrii przepływowej

Challenging Diagnosis in Hematopathology

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.

Non-Hodgkin s lymphoma. Univ. Prof. Dr. Werner Linkesch Univ. Klinik Graz

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

What to know about the B-cell neoplasms Steven H. Swerdlow, M.D.

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Cord blood Banking Transplant List for One USA Bank - StemCyte

Understanding Non-Hodgkin Lymphoma

SEER SINQ s. Finalized March 2011

6/20/2014. PART I: Plasma Cell Myeloma. Plasma Cells

Flow Cytometry A Guide for Data Analysis

Histopathologic results

Activation and effector functions of HMI

Transformation in Malignant Lymphoma: Morphologic Approach* **

Excellent FFPE. Staining

Non-Hodgkin Lymphoma Richard Orlowski, MD

Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic

NEOPLASMS C00 D49. Presented by Jan Halloran CCS

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Non-Hodgkin Lymphoma

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

Hematology Morphology Critique

Locoregional & advanced esophagus or esophagogastric junction cancer

Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

YOUR LUNG CANCER PATHOLOGY REPORT

Dako provides cancer diagnostic products for leading reference laboratories, hospitals and other clinical and research settings.

Frequency of NHL Subtypes in Adults

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO Gundersen Health System Center for Cancer and

LCD for Erythrocyte Sedimentation Rate (ESR)

Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma

Non-Hodgkin Lymphoma in Queensland An Overview 2012

Outline of lecture. Disclosures. Current Issues in Practical Hematopathology: Diagnosis of Bone Marrow Lymphomas


Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo

PERIPHERAL SMEARS: THE PRIMARY DIAGNOSTIC TOOL PART II IRMA PEREIRA, MT(ASCP)SH

co-sponsored by the Health & Physical Education Department, the Health Services Office, and the Student Development Center

Stem Cell Transplantation

DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES

Immunophenotyping in the differential diagnosis of histologically low grade B cell lymphomas

Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma

Immunophenotypic Analysis of Peripheral T-Cell Neoplasms A Multiparameter Flow Cytometric Approach

FastTest. You ve read the book now test yourself

Pathology of lung cancer

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Things You Don t Want to Miss in Multiple Myeloma

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics

What Leukemia Is. Understanding blood

OBJECTIVES By the end of this segment, the community participant will be able to:

Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy.

ICD-10 FREQUENTLY ASKED QUESTIONS

Update on Mesothelioma

Update on Diagnosis and Treatment of Lymphoma

Acute leukemias and myeloproliferative neoplasms

Seattle. Case Presentations. Case year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?

Interesting Case Series. Periorbital Richter Syndrome

Lymphoma: An Overview. Dr Louise Connell 05/03/2103

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012

Recognition of T cell epitopes (Abbas Chapter 6)

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

New Hampshire Childhood Cancer

Overview. Transcriptional cascades. Amazing aspects of lineage plasticity. Conventional (B2) B cell development

Update in Hematology Oncology Targeted Therapies. Mark Holguin

CASE 2. Seven week old female infant presents with hepatosplenomegaly l and WBC 31.0k/mm 3, Hgb 9.2 g/dl, Plt 110k/mm 3 with 60% blasts

Anti-HCV therapy in HCV-related NHL

Transcription:

Cutaneous Lymphoma Curtis T. Thompson, MD 6/9/2010 WHO-EORTC CLASSIFICATION OF CUTANEOUS LYMPHOMAS WITH PRIMARY CUTANEOUS MANIFESTATIONS (2005) 1. Addresses differences with WHO classification (2008) for all lymphomas 2. Uses Dutch/Austrian frequency and survival data 3. 1:100,000 annual incidence (#2 after GI tract) CUTANEOUS T-CELL AND NK-CELL LYMPHOMAS (CD3) Mycosis fungoides 1. 50% of all primary cutaneous lymphomas a. Important to stage patient <10% BSA; Tumor, Systemic 2. Reserve term for classical "Alibert-Bazin" type--(patch/plaque/tumor progression) other tumors have epidermotrophism. 3. Older, buttock, slow progression if present with tumors, not MF 4. Histology a. Epidermotropism i. Pearls on a string (basalis) ii. Pautrier s microabscesses often not present; may low upward scatter with progression to tumor stage b. CD3+, CD4+CD7-CD8- (most common) i. CD3-panT; CD4-Thelper, CD8 ii. Loss of Antigen (CD7, CD26); Gain (CD2,CD3,CD5) c. Clonality usually present same clone at different sites (useful for diagnostics) d. 10q and abnormalities in p15, p16, and p53 tumor suppressor genes. 5. Transformation a. >30% large cells (blasts) can be CD30+ or neg doesn t matter b. Gain cytotoxic proteins--t-cell intracellular antigen-1 [TIA-1], granzyme B

Curtis Thompson, M.D. Cutaneous Lymphoma 2 6. MF variants and subtypes a. Folliculotropic MF adult men, like tumor stage MF treat deeper (electron beam) i. vs follicular mucinosis (alopecia mucinosa)-difficult ii. clonality not helpful Other T-cell Lymphomas b. Pagetoid reticulosis i. Large epidermotropic cells (localized type (Woringer-Kolopp type) localized (hand/arm) (not disseminated Ketron-Goodman type) ii. CD4+ or CD8+. c. Granulomatous slack skin rare, CD4+--granulomatous/epidermotropic, specific clinical d. Sézary syndrome diagnose with flow cytometry and clonality studies i. Absolute Sézary cell count of least 1000 cells/mm 3 ii. CD4/CD8 ratio > 10 iii. Loss of CD2, CD3, CD4, CD5 or CD7 Primary cutaneous CD30+ lymphoproliferative disorders 30% of all lymphoma most of remaining after MF 1. Primary cutaneous anaplastic large cell lymphoma vs Lymphomatoid papulosis (LyP) a. Clinical and histologic distinction b. CD4+, CD30+ (Concept: Any large hematopoietic cell can be CD30+) c. No anaplastic lymphoma kinase (ALK) (2;5)(p23;q35) translocation) seen in systemic anaplastic; d. No CD15 (Hodgkin s)

Curtis Thompson, M.D. Cutaneous Lymphoma 3 e. LyP Histology (Willemze A and B older classification) i. Type A Reed-Sternberg-like (owl eyes) (CD30+) ii. Type B MF like cerebriform CD30 negative iii. Type C Monotonous large cluster of CD30+ cells--rare Subcutaneous panniculitis-like T-cell lymphoma 1. Legs, careful with diagnosis of LE profundus 2. Histo septal and lobular rimming or adipocytes helpful 3. Two clinical variants a. / + T-cell phenotype (75%) indolent i. Gene rearrangement important in diagnostics ii. CD8 + iii. Subcutaneous only (no dermal/epidermal) iv. / (gamma/delta) T-cell phenotype (25%--now has own designation see below)

Curtis Thompson, M.D. Cutaneous Lymphoma 4 Cutaneous / (Gamma/delta) T-cell lymphoma (provisional) 1. Aggressive not useful to classify as primary cutaneous or systemic; hemophagocytic syndrome 2. CD56+ pluse cytotoxic proteins (TIA-1, granzyme B, perforin) 3. TCR gamma rearrangement (not beta) 4. Can involve all levels of skin (epidermis/dermis/subcutis) may affect prognosis--?subcutaneous only worse? Extranodal NK/T-cell lymphoma, nasal type 1. Asia/Latin America, adults 2. Not useful to separate from nasal 3. Histology Angiodestructive 4. CD56+, EBV+ Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (provisional) 1. CD8 plus cytotoxic proteins (TIA-1, granzyme B, perforin) 2. Think of this when see pagetoid reticulosis Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (provisional) 1. May have been called Tumor stage MF in prior years 2. Upper body 3. Fairly good prognosis excise or XRT. Adult T-cell leukemia/lymphoma a. HTLV-1, b. Acute (systemic) vs smoldering skin only tx smoldering like MF c. CD4+, ++CD25 (board question) Primary cutaneous peripheral T-cell lymphoma, unspecified Trash can for unclassifiable lymphomas. CUTANEOUS B-CELL LYMPHOMAS (CD20, CD79a) Primary cutaneous marginal zone B-cell lymphoma 1. Clinical multiple lesions, trunk/arms, ulceration a. Helps in distinguishing from cutaneous lymphoid hyperplasia (aka Pseudolymphoma) both have 100% survival-?? b. Borrelia burgdorferi association in Europe 2. Marginal zone edge of follicle (centrocyte) formerly called immunocytoma 3. Plasma cells light chain restriction only kappa or lambda (Normal 2:1 κ:γ) 4. Don t get same tranlocation as other MALT lymphomas get t(14;18)(q32;q21) (IGH and MLT genes) and t(3;14)(p14.1;q32) (IGH and FOXP1) Primary cutaneous follicle center lymphoma 1. Clinical Scalp/trunk single lesion good prognosis with XRT 2. Histo Follicles with epidermal sparing can have blasts (Centroblasts, Immunoblasts) 3. bcl-6 no macrophages in follicles ( tangible ) 4. No bcl-2 or t(14;18) translocation, as seen in systemic. Primary cutaneous diffuse large B-cell lymphoma, leg type

Curtis Thompson, M.D. Cutaneous Lymphoma 5 1. Elderly bad prognosis 2. Diffuse, large cells (centroblasts) 3. bcl-2 positive; no t(14;18) Intravascular large B-cell lymphoma 1. Usually systemic rare cutaneous only can look angiomatous 2. CD20+ cells in vessels Primary cutaneous diffuse large B-cell lymphoma, other Trash can PRECURSOR HEMATOLOGIC NEOPLASM CD4+/CD56+ hematodermic neoplasm (formerly blastic NK-cell lymphoma but not an NK cell) 1. Plasmacytoid dendritic cell cell of origin 2. 50% marrow involvement differentiated from myelomonocytic leukemia 3. EBV negative 4. Treat like leukemia OTHER Cutaneous Lymphoid Hyperplasia (CLH) (Pseudolymphoma) 1. Single or multiple lesions old bite consider complete excision. 2. B-cells (CD20) and T-cells (CD3) 3. CD21 highlights germinal centers (follicular dendritic cells) 4. CD10 and bcl-6 highlight ONLY germinal centers (Follicular lymphoma highlights beyond) 5. Can show clonality Leukemia cutis histology plus IHC studies 1. CD34 hits many cells 2. tdt--can hit other lymphomas 3. Myeloperoxidase anything myeloid (neutrophils, etc) Flow Cytometry Consider this as a diagnostic tool when you have EQUIVOCAL biopsy results and a cellular infiltrate. 1. Able to test many more antigens better sensitivity/specificity 2. Able to look at 2 or more antigens at once (co-expression) 3. 4mm punch mince and place in RPMI media (tissue culture media which can be obtained from the flow lab. Also, sending the biopsy fresh immediately to the lab also works.

Curtis Thompson, M.D. Cutaneous Lymphoma 6 CONCEPTS: 1. Clonality Malignancy 2. Antigens: Can have loss of gain of antigens in malignancy used in diagnostics (i.e. CD4+CD7- in MF). 3. CD30 is expressed by many large cells (blasts) not specific can be associated with reactive (B9) processes. 4. Don t overdiagnose MF don t scare patients. 5. Don t let the pathologist spend too much time working up an aggressive looking process. 6. If it isn t acting benign (pseudolymphoma), it might be malignant. 7. Primary cutaneous B-cell lymphoma is quite rare much more common to have secondary involvement of skin by systemic lymphoma. Send the patient to an oncologist as soon as you suspect a B-cell lymphoma for a pan-man-scan.

Curtis Thompson, M.D. Cutaneous Lymphoma 7 References Willemze R et al. WHO-EORTC classification for cutaneous lymphomas. Blood, 15 May 2005, Vol. 105, No. 10, pp. 3768-3785.